Alexandra Leutbecher

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: September 24, 2024

Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer.

Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer.

Journal: Scientific reports

Published: October 22, 2023

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Journal: Leukemia

Published: October 21, 2023

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

Journal: Blood

Published: March 21, 2022

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection.

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection.

Journal: Nature communications

Published: August 31, 2021

Impaired function and delayed regeneration of dendritic cells in COVID-19.

Impaired function and delayed regeneration of dendritic cells in COVID-19.

Journal: PLoS pathogens

Published: June 28, 2021

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.

Journal: Journal of hematology & oncology

Published: March 05, 2021

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.

Journal: HemaSphere

Published: January 21, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026